Astrid Nehlig1,2, Nathalie Reix3,4, Pauline Arbogast5, Carole Mathelin5,6. 1. INSERM U 1129, Pediatric Neurology, Necker Hospital for Sick Children, University of Paris Descartes, Paris, France. 2. Faculty of Medicine, Strasbourg, France. 3. Faculty of Medicine, ICube UMR 7357, University of Strasbourg/CNRS, Federation of Translational Medicine of Strasbourg (FMTS), Strasbourg, France. nathalie.reix@chru-strasbourg.fr. 4. Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, Strasbourg, France. nathalie.reix@chru-strasbourg.fr. 5. Surgery Unit, Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France. 6. Department of Functional Genomics and Cancer, Institute of Genetics and Cellular and Molecular Biology, University of Strasbourg, Illkirch, France.
Abstract
PURPOSE: Most of the existing literature reports no association or a slight negative association between coffee consumption and the risk of developing breast cancer. However, the level of risk differs when considering various subgroups, such as menopausal status, hormonal status of the tumor or genetic mutations. The present review based on a literature search sets the point on the potential influence of a common daily drink, coffee, on the risk of developing breast cancer in the general population, in different subgroups of women and the consequences of drinking coffee after breast cancer has been diagnosed and treated. RESULTS: This review confirms that in the general population, there is no association between coffee intake and breast cancer risk or a slight protective effect, even at high dosages. Coffee is inversely associated with breast cancer risk in postmenopausal women and in women carrying a BRCA1 mutation. Possible risk differences exist between slow and fast caffeine metabolizers and with weight. Coffee consumption after breast cancer diagnosis and surgery, associated with tamoxifen and/or radiotherapy, reduced the occurrence of early events. The effects of coffee intake are less clear in other subgroups, mainly premenopausal women, women carrying a BRCA2 mutation and tumors with variable hormonal status (positive or negative for ER/PR) and would need additional studies.
PURPOSE: Most of the existing literature reports no association or a slight negative association between coffee consumption and the risk of developing breast cancer. However, the level of risk differs when considering various subgroups, such as menopausal status, hormonal status of the tumor or genetic mutations. The present review based on a literature search sets the point on the potential influence of a common daily drink, coffee, on the risk of developing breast cancer in the general population, in different subgroups of women and the consequences of drinking coffee after breast cancer has been diagnosed and treated. RESULTS: This review confirms that in the general population, there is no association between coffee intake and breast cancer risk or a slight protective effect, even at high dosages. Coffee is inversely associated with breast cancer risk in postmenopausal women and in women carrying a BRCA1 mutation. Possible risk differences exist between slow and fast caffeine metabolizers and with weight. Coffee consumption after breast cancer diagnosis and surgery, associated with tamoxifen and/or radiotherapy, reduced the occurrence of early events. The effects of coffee intake are less clear in other subgroups, mainly premenopausal women, women carrying a BRCA2 mutation and tumors with variable hormonal status (positive or negative for ER/PR) and would need additional studies.
Entities:
Keywords:
BRCA mutations; Breast cancer; Coffee; Hormonal status; Menopause; Tamoxifen
Authors: Xiu Juan Li; Zhao Jun Ren; Jian Wei Qin; Jian Hua Zhao; Jin Hai Tang; Ming Hua Ji; Jian Zhong Wu Journal: PLoS One Date: 2013-01-04 Impact factor: 3.240
Authors: Firas S Azzeh; Deena M Hasanain; Alaa H Qadhi; Khloud J Ghafouri; Wedad F Azhar; Mazen M Ghaith; Abdullah F Aldairi; Hussain A Almasmoum; Hamza M Assaggaf; Maha H Alhussain; Ahmad A Alghamdi; Mahmoud M Habibullah; Waleed M Bawazir; Sofyan S Maghaydah; Maysoun S Qutob; Awfa Y Alazzeh Journal: Front Nutr Date: 2022-04-18